Indivior Announces Patent Trial and Appeal Board Ruling in Dr. Reddy’s Laboratories (DRL)’s Petition for Inter Partes Review of U.S. Patent No. 9,687,454 (the ‘454 Patent)
June 3, 2020 | PDF Version
May 14, 2020 | PDF Version
Indivior receives approval for SUBUTEX® prolonged release solution for injection, 100mg and 300mg for substitution treatment of opioid dependence in Sweden
May 6, 2020 | PDF Version
April 27, 2020 | PDF Version
Updates on the Department of Justice Action
Get updates and information on Indivior’s ongoing response to the recent action by the U.S. Department of Justice and learn about the company’s unwavering commitment to patients, doctors, and communities fighting opioid addiction.
See more >
Click on the headings to view online or download a presentation:
View Indivior filings with the Regulatory News Service on regulatory and non-regulatory updates.
View Indivior Annual Reports